2,578 Amgen Inc. $AMGN Shares Acquired by Soltis Investment Advisors LLC

Soltis Investment Advisors LLC lifted its position in Amgen Inc. (NASDAQ:AMGN) by 8.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 31,750 shares of the medical research company’s stock after acquiring an additional 2,578 shares during the quarter. Amgen accounts for 0.6% of Soltis Investment Advisors LLC’s portfolio, making the stock its 28th largest position. Soltis Investment Advisors LLC’s holdings in Amgen were worth $13,383,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. Choreo LLC raised its holdings in shares of Amgen by 1.5% in the third quarter. Choreo LLC now owns 18,598 shares of the medical research company’s stock worth $7,839,000 after buying an additional 278 shares during the period. Interchange Capital Partners LLC boosted its holdings in Amgen by 1.3% during the 3rd quarter. Interchange Capital Partners LLC now owns 2,139 shares of the medical research company’s stock valued at $902,000 after acquiring an additional 28 shares during the period. Livelsberger Financial Advisory purchased a new position in Amgen during the 3rd quarter valued at $74,000. China Universal Asset Management Co. Ltd. grew its position in Amgen by 0.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 72,485 shares of the medical research company’s stock valued at $30,708,000 after acquiring an additional 282 shares during the last quarter. Finally, TOWER TRUST & INVESTMENT Co bought a new position in Amgen in the 3rd quarter valued at $38,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Rachna Khosla sold 1,252 shares of Amgen stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the transaction, the senior vice president owned 6,404 shares in the company, valued at $2,666,817.72. This represents a 16.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 6,222 shares of company stock valued at $2,540,926 in the last ninety days. Corporate insiders own 0.85% of the company’s stock.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Analyst support: RBC Capital reaffirmed its Buy rating, while Goldman Sachs and TD Cowen also maintained Buy recommendations. The continued bullish view provides support ahead of earnings. RBC Capital Reaffirms Buy Rating
• Positive Sentiment: Rare-disease pipeline progress: Amgen reported Phase 3 data for dazodalibep in Sjögren’s disease, additional long-term UPLIZNA data in IgG4-related disease and other autoimmune conditions, and a diagnostic collaboration aimed at earlier rare-disease detection. The updates reinforce the company’s effort to expand growth beyond its established products. Rare Disease Updates
• Positive Sentiment: Dividend income: Amgen declared a quarterly dividend of $2.52 per share, or $10.08 annualized, payable December 11 to shareholders of record November 20. The dividend supports the stock’s income appeal. Amgen Fourth-Quarter Dividend
• Neutral Sentiment: Earnings catalyst: Amgen will report third-quarter 2026 results after the market close on November 3, followed by a conference call. Analysts are focused on whether strong sales of products such as Repatha and TEZSPIRE can offset rising expenses, pricing pressure and biosimilar competition. Amgen Third-Quarter Results Announcement
• Negative Sentiment: Profitability concerns: Management has warned that spending will increase, while MariTide trials could consume substantial cash. Investors are assessing whether higher research and development costs and a CFO transition could pressure margins. Amgen Expense and Profit Outlook

Analyst Upgrades and Downgrades

AMGN has been the topic of a number of recent analyst reports. Royal Bank Of Canada increased their target price on Amgen from $400.00 to $430.00 and gave the stock an “outperform” rating in a research note on Thursday, October 8th. Scotiabank boosted their target price on shares of Amgen from $450.00 to $500.00 and gave the company an “outperform” rating in a research note on Monday, September 28th. Robert W. Baird upped their price target on shares of Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a report on Wednesday, August 5th. Bank of America raised their price target on shares of Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 5th. Finally, Canaccord Genuity Group lifted their price objective on shares of Amgen from $366.00 to $384.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $389.71.

Amgen Stock Performance

AMGN stock opened at $460.73 on Friday. Amgen Inc. has a 1-year low of $288.00 and a 1-year high of $468.27. The business has a 50-day moving average price of $419.32 and a 200 day moving average price of $374.09. The company has a market capitalization of $249.08 billion, a P/E ratio of 28.63, a PEG ratio of 3.31 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. The company had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm’s quarterly revenue was up 9.5% on a year-over-year basis. During the same period in the prior year, the business earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities research analysts forecast that Amgen Inc. will post 22.96 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be given a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Friday, November 20th. Amgen’s dividend payout ratio is presently 62.65%.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.